Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;32(9):1620-5.
doi: 10.2337/dc08-2175. Epub 2009 Jun 29.

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

Gillian Libby  1 , Louise A Donnelly, Peter T Donnan, Dario R Alessi, Andrew D Morris, Josie M M Evans
Affiliations

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

Gillian Libby et al. Diabetes Care. 2009 Sep.

Abstract

Objective: The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes.

Research design and methods: In an observational cohort study using record-linkage databases and based in Tayside, Scotland, U.K., we identified people with type 2 diabetes who were new users of metformin in 1994-2003. We also identified a set of diabetic comparators, individually matched to the metformin users by year of diabetes diagnosis, who had never used metformin. In a survival analysis we calculated hazard ratios for diagnosis of cancer, adjusted for baseline characteristics of the two groups using Cox regression.

Results: Cancer was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times to cancer of 3.5 and 2.6 years, respectively (P < 0.001). The unadjusted hazard ratio (95% CI) for cancer was 0.46 (0.40-0.53). After adjusting for sex, age, BMI, A1C, deprivation, smoking, and other drug use, there was still a significantly reduced risk of cancer associated with metformin: 0.63 (0.53-0.75).

Conclusions: These results suggest that metformin use may be associated with a reduced risk of cancer. A randomized trial is needed to assess whether metformin is protective in a population at high risk for cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart showing how metformin users and comparators were selected for the study.
Figure 2
Figure 2
Kaplan-Meier plot with 95% CIs showing time to cancer among metformin users and comparators.
See this image and copyright information in PMC

Comment in

References

    1. Hardie DG: AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007; 47: 185– 210 - PubMed
    1. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Stabdop J, Ding XZ, Adrian TE, Pour PM: Prevention of pancreatic induction in hamsters by metformin. Gastroenterology 2001; 120: 1263– 1270 - PubMed
    1. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko IV: Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005; 139: 721– 723 - PubMed
    1. Huang X, Wellschleger S, Shapiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412: 211– 221 - PubMed
    1. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase–dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10267– 10273 - PubMed

Publication types